Method of prognosis
AssigneesAlfred Health, Peking University Third Hospital
InventorsANTHONY DART, Wei GAO
Life of this patent
Estimating the term…
Abstract
Provided is a method for prognosing ACS in a subject, the method comprising determining plasma MIF and Nt-ProBNP (or BNP) concentrations in a sample from the subject, diagnosing ACS when the subject plasma concentrations are greater than a reference MIF and Nt-proBNP (or BNP) plasma concentration, and prognosing the magnitude of ACS from the subject plasma MIF and Nt-proBNP (or BNP) concentrations. Also provided are a device, a kit and a cardiac biomarker panel related to the methods of prognosing ACS.
Claims41
A method for providing a prognosis of acute coronary syndrome (ACS) in a subject comprising
- determining the concentration of (a) macrophage migration inhibitory factor (MIF) or fragment thereof, and (b) N-terminal prohormone of brain natriuretic peptide (Nt-proBNP) or a fragment thereof, in a sample from the subject, and
- prognosing ACS when the subject plasma MIF and Nt-proBNP concentration is greater than a reference plasma MIF and Nt-proBNP concentration.
A method for providing a prognosis of a subject having acute coronary syndrome (ACS), the method comprising:
- determining the concentration of (a) macrophage migration inhibitory factor (MIF) or fragment thereof, and (b) N-terminal prohormone of brain natriuretic peptide (Nt-proBNP) or a fragment thereof, in a sample from the subject,
- comparing the concentration of MIF or fragment thereof to a reference MIF concentration,
- comparing the concentration of Nt-proBNP or fragment thereof to a reference Nt-proBNP concentration,
- wherein the concentration of MIF or fragment thereof and Nt-proBNP or fragment thereof compared to their respective reference concentrations is indicative of the subject's prognosis.
A method for providing a prognosis of a subject having ACS, the method comprising
- determining the concentration of (a) macrophage migration inhibitory factor (MIF) or fragment thereof, and (b) N-terminal prohormone of brain natriuretic peptide (Nt-proBNP) or a fragment thereof, in a sample from the subject,
- comparing the concentration of MIF or fragment thereof to a reference MIF concentration,
- comparing the concentration of Nt-proBNP or fragment thereof to a reference Nt-proBNP concentration,
- wherein the reference concentrations of MIF and Nt-proBNP are concentrations below which correlate with an increased probability of survival and a decreased probability of non-fatal cardiac events at a later time, and above which correlate with a decreased probability of survival and an increased probability of non-fatal cardiac events at a later time,
- thereby providing a prognosis of a subject having ACS.
A method for providing a prognosis of a subject having ACS, the method comprising
- analysing levels of (a) macrophage migration inhibitory factor (MIF) or fragment thereof and (b) B N-terminal prohormone of brain natriuretic peptide (Nt-proBNP) or a fragment thereof, in a sample from the subject
- determining the concentration of macrophage migration inhibitory factor (MIF) or fragment thereof and N-terminal prohormone of brain natriuretic peptide (Nt-proBNP) or a fragment thereof in the sample from the subject,
- comparing the concentration of MIF or fragment thereof to a reference MIF concentration,
- comparing the concentration of Nt-proBNP or fragment thereof to a reference Nt-proBNP concentration,
- assigning the subject to a risk group based on whether the concentration of MIF or fragment thereof is higher or lower than the reference concentration, and whether the concentration of Nt-proBNP or fragment thereof is higher or lower than the reference concentration,
- wherein a concentration of MIF or fragment thereof that is higher than the reference MIF concentration indicates a low likelihood of survival and high likelihood of non-fatal cardiac events,
- wherein a concentration of Nt-proBNP or fragment thereof that is higher than the reference Nt-proBNP concentration indicates a low likelihood of survival and high likelihood of non-fatal cardiac events,
- thereby providing a prognosis of a subject having ACS.
A method for providing a prognosis of a subject having ACS, the method comprising
- determining the concentration of macrophage migration inhibitory factor (MIF) or a fragment thereof in a sample from the subject,
- wherein if the concentration of MIF or fragment thereof from the sample from the subject is equal to or higher than about 70 ng/ml the subject is determined to have a decreased probability of survival and an increased probability of non-fatal cardiac events at a later time,
- wherein if the concentration of MIF or fragment thereof from the sample from the subject is lower than about 70 ng/ml the subject is determined to have an increased probability of survival and a decreased probability of non-fatal cardiac events at a later time,
- thereby providing a prognosis of a subject having ACS.
A method for providing a prognosis of a subject having ACS, the method comprising
- determining the concentration of macrophage migration inhibitory factor (MIF) or a fragment thereof in a sample from the subject,
- comparing the concentration of MIF or fragment thereof to reference MIF concentrations of about 40 ng/ml and about 70 ng/ml,
- wherein if the concentration of MIF or fragment thereof from the sample from the subject is equal to or lower than about 40 ng/ml the subject is determined to have a high probability of survival and a low probability of non-fatal cardiac events at a later time,
- wherein if the concentration of MIF or fragment thereof from the sample from the subject is equal to or higher than about 70 ng/ml the subject is determined to have a low probability of survival and a high probability of non-fatal cardiac events at a later time,
- thereby providing a prognosis of a subject having ACS.
A method of treating acute coronary syndrome (ACS) in a subject, the method comprising:
- (a) determining macrophage migration inhibitory factor (MIF) or fragment thereof and N-terminal prohormone of brain natriuretic peptide (Nt-proBNP) or fragment thereof concentration in a sample taken from the subject, and prognosing ACS when the subject MIF and Nt-proBNP concentration is greater than a reference MIF and Nt-proBNP concentration;
- and
- (b) performing percutaneous coronary intervention (PCI) and/or thrombinolysis on the subject.
A cardiac biomarker panel comprising plasma macrophage migration inhibitory factor (MIF) and N-terminal prohormone of brain natriuretic peptide (Nt-proBNP) in a sample from a subject, wherein MIF and Nt-proBNP concentrations greater than reference MIF and Nt-proBNP concentrations are prognostic of the magnitude of ACS in the subject.
Dependencies are inferred from the claim text.